724MO Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): Final results from a phase II study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC)

Second-line treatment for R/M CC continues to present a major clinical challenge. Dual blockade of the PD-1 and CTLA-4 immune checkpoints is a validated therapeutic strategy for multiple malignancies. Here we present mature findings of a large single arm Phase II study evaluating the safety and antitumor activity of the anti-PD-1 antibody balstilimab (bal) plus the anti-CTLA-4 antibody zalifrelimab (zal) in pts with R/M CC.